• Aluminium pouches with a Microwell Plate coated with antibody to human TSLP (8X12)
• 2 vials human TSLP Standard lyophilized, 500 pg/ml upon reconstitution
• 2 vials concentrated Biotin-Conjugate anti-human TSLP antibody
• 2 vials Streptavidin-HRP solution
• 1 bottle Standard /sample Diluent
• 1 bottle Biotin-Conjugate antibody Diluent
• 1 bottle Streptavidin-HRP Diluent
• 1 bottle Wash Buffer Concentrate 20x (PBS with 1% Tween-20)
• 1 vial Substrate Solution
• 1 vial Stop Solution
• 4 pieces Adhesive Films
• package insert

Thymic Stromal Lymphopoietin (TSLP) is a 23 kDa member of the IL-7 family of a-helical cytokines (1-3). It is a monomeric glycoprotein that is synthesized as a 159 amino acid (aa) precursor (4, 5). TSLP appears to have species-specific functions. In mouse, TSLP was initially reported to act on NK cells, mast cells, and B cells, but this does not appear to occur in humans. In humans, TSLP is produced by a number of divergent cell types, all of which appear to target T cells, monocytes, and/or dendritic cells (2). On TCR-activated T cells, TSLP directly induces T cell proliferation (6). The significance of this direct action is unclear. On monocytes, TSLP is reported to induce the release of multiple chemokines that target CCR4, a receptor associated with the Th2 subset (5). TSLP is best known for its direct action on subsets of dendritic cells. In thymic medulla, Hassell

Liu, Y-J. et al. (2007) Annu. Rev. Immunol. 25:193.

Liu, Y-J. (2006) J. Exp. Med. 203:269.

Ziegler, S.F. and Y-J. Liu. (2006) Nat. Immunol. 7:709.

Quentmeier, H. et al. (2001) Leukemia 15:1286.

Reche, P.A. et al. (2001) J. Immunol. 167:336.

Rochman, I. et al. (2007) J. Immunol. 178:6720.

Watanabe, N. et al. (2005) Nature 436:1181.

Ebner, S. et al. (2007) J. Clin. Allergy Immunol. 119:982.

Soumelis, V. et al. (2002) Nat. Immunol. 3:673.